Purpose
To evaluate the effectiveness of transarterial chemoembolization (TACE) in patients with hepatic metastases from lung cancer regarding local tumor control and survival.
Methods and Materials
21 patients with unresectable hepatic metastases of lung cancer were repeatedly treated with TACE in 4-week intervals (86 chemoembolizations,
mean: 4.1 sessions/patient).
At the time of first chemoembolization,
the average age of patients was 53.3 (range,
28-75).
85.7% (18/21) of patients showed multiple metastases,
14.3% (3/21) had 2-3 metastases.
The local chemotherapy protocol consisted of mitomycin (n=7),
and mitomycin with gemcitabine (n=14).
Embolization was performed with lipiodol and starch microspheres for vessel occlusion.
Tumor response was evaluated by MRI.
Change in size was calculated and...
Results
Local tumor control showed partial response in 14.3% (3/21),
stable disease in 47.6% (10/21),
and progressive disease in 38.1% (8/21).
During the course of therapy the clinical situation changed: 17 patients (81%) were treated palliatively,
4 patients (19%) symptomatically.One-year survival rate after TACE was 47%,
2-year survival rate was reduced to 6%.
Median and mean survival from the time of diagnosis were 22 and 32 months (according to Kaplan-Meier),
and from the start of TACE treatment 11.5 and 14.1 months.
Median survival of patients after...
Conclusion
TACE is a safe minimal-invasive treatment for patients with liver metastases from lung cancer.
References
Rofo.2007 Mar;179(3):300-7.
[Palliative treatment of primary lung tumors with transpulmonary chemoembolization (TPCE)].
[Article in German]Vogl TJ,
Herzog C,
Zangos S,
Lindemayr S.
Radiologe.2009 Sep;49(9):837-41.
[C-arm computed tomography for transarterial chemoperfusion and chemo-embolization of thoracic lesions].
[Article in German]Vogl TJ,
Naguib NN,
Nour-Eldin NE,
Lehnert T,
Mbalisike E.
Abstract
PURPOSE:
To evaluate the role of C-armCT for on-line fluoroscopy in regional transarterial chemoperfusion (TACP) and chemo-embolization (TPCE) of primary and secondary malignant thoracic lesions.
MATERIALS AND METHODS:
From September 2008 to March 2009 a total of...
